Lindsay Androski, JD, MBA, CFA

Lindsay Androski, JD, MBA, CFA is President and CEO of Roivant Social Ventures, the social impact arm of Roivant Sciences. She joined the founding team of Roivant in early 2016, where she built and led the team responsible for the in-license or acquisition of more than 30 pharmaceutical drug candidates. Ms. Androski was instrumental in the launch of 16 biotechs and participated in three IPOs and the then-largest-ever private biotech financing ($1.1 billion). To date, five drug candidates acquired by Ms. Androski’s team have been approved by FDA: Orgovyx (prostate cancer), Myfembree (heavy menstrual bleeding / uterine fibroids), Gemtesa (overactive bladder), Rethymic (pediatric congenital athymia), and VTAMA (plaque psoriasis). Ms. Androski also built and led the intellectual property team across the portfolio of companies, and led hiring of CEOs and CMOs for subsidiary companies, partnership efforts in Japan and China, and alliance management across the Roivant family of companies.

Ms. Androski serves as a Trustee of MIT, Chair of the MIT Visiting Committee for the Department of Chemistry, and member of the Visiting Committees for Sponsored Research, the Department of Biology, and the Department of Humanities. She is Board President of Incubate, an advocacy organization that educates lawmakers on the critical role of venture capital in biopharma, and serves as a Director of Eloxx Pharma, where she sits on the Audit and Compensation Committees. Ms. Androski teaches ESG Investing in the Department of Economics of Duke University.